Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting
Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually. Copies of the poster and oral presentation are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations.
Apollomics股份有限公司（納斯達克股票代碼：APLM）（“Apollomics”或“公司”），是一家臨床前期生物製藥公司，開發多個腫瘤藥物候選品，以治療難以治療和耐藥的癌症，宣佈伴侶公司Avistone生物技術將在2024年美國臨床腫瘤學會（ASCO）年度會議上進行海報報告和口頭報告，該會議將於2024年5月31日至6月4日在伊利諾伊州芝加哥舉行。海報和口頭報告的副本可在Apollomics網站的ir.apollomicsinc.com/news-events/presentations上獲取。
譯文內容由第三人軟體翻譯。